The 35th European Society of Medical Oncology congress, taking place in Milan, Italy, has seen a batch of clinical trial results on both already marketed cancer drugs and some still in development, and the following is a summary of some of these presentations.
Roche’s MetMAb slows disease progression
Swiss drug major Roche (ROG: VX) announced new data at the ESMO showing that MetMAb, a monovalent antagonist antibody, plus Tarceva (erlotinib) nearly doubled the time people with high MET-expressing non-small cell lung cancer lived without their disease progression compared to placebo plus Tarceva (HR=0.560, p=0.0547). The median PFS was improved from 6.4 weeks to 12.4 weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze